Health ❯ Healthcare ❯ Research Studies

Phase 3 Trials

Efficacy and Safety ESSENCE Trial SURMOUNT-5 Study Efficacy Comparisons IGNYTE-3 Trial ASCENT-07 Study KEYNOTE-937 HERIZON-GEA-01 MajesTEC-9 Study

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

Regulatory discussions are planned following independent confirmation of benefit.

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

Replimune Reports No Defined Accelerated-Approval Path After FDA Type A Meeting on RP1 for Melanoma